Treatment-resistant Depression drug
Feb 21, 2025
J&J’s SPRAVATO Achieves Milestone with Monotherapy Approval in Depression Treatment
Johnson & Johnson’s SPRAVATO, which is already on track to become a blockbuster drug, has received a significant boost with the FDA’s approval for its use as a standalone treatment for major depressive disorder (MDD). Initially approved in 2019, SPRAVATO was authorized for use alongside an oral antidepressant i...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
